Izana Bioscience Set Up For Ankylosing Spondylitis Breakthrough
Executive Summary
A new UK company set up by entrepreneur Bryan Morton to develop an innovative medicine for ankylosing spondylitis may be an example of how start-up companies could be supported through the UK's just announced industrial strategy for the life sciences sector.
You may also be interested in...
Will ‘Transformative’ UK Life Sciences Sector Deal Help Offset The Brexit Effect?
The UK government has published its life sciences sector deal, which it says will allow the UK to respond to the challenges and opportunities of demographic change and pioneering research and development – although there is no mention of the “Brexit effect.”
Takeda's Deal Flurry Set To Wane
Takeda's reorganization and the focusing of its R&D on specialty medicines in three sectors is shifting to the next stage, with products moving through its pipeline; the company has lifted its financial outlook at the six-month stage, but is wary of the emergence of US generic competition to Velcade later this year.
EUSA Pharma Aims To Grow Through Acquisitions In Specialty Rx Market
EUSA Pharma announced the launch of operations March 23 with a group of products acquired from Jazz Pharmaceuticals and funding from equity investor Essex Woodlands; it is the third specialty pharma company set up by U.K. entrepreneur Bryan Morton.